Filing Details
- Accession Number:
- 0001209191-16-147480
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-10-31 16:48:16
- Reporting Period:
- 2016-10-31
- Filing Date:
- 2016-10-31
- Accepted Time:
- 2016-10-31 16:48:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1481512 | Ra Pharmaceuticals Inc. | RARX | () | E9 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1452907 | New Enterprise Associates 13 Lp | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No | |
1460751 | Nea 13 Gp, Ltd | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No | |
1460752 | Nea Partners 13, Limited Partnership | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-10-31 | 80,658 | $0.07 | 80,658 | No | 4 | X | Direct | |
Common Stock | Disposition | 2016-10-31 | 435 | $13.00 | 80,223 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2016-10-31 | 1,778,227 | $0.00 | 1,858,450 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2016-10-31 | 669,951 | $0.00 | 2,528,401 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2016-10-31 | 623,210 | $0.00 | 3,151,611 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2016-10-31 | 338,462 | $13.00 | 3,490,073 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | X | Direct | |
No | 4 | S | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants to Purchase Common Stock | Disposition | 2016-10-31 | 80,658 | $0.00 | 80,658 | $0.07 |
Common Stock | Series A Preferred Stock | Disposition | 2016-10-31 | 12,447,605 | $0.00 | 1,778,227 | $0.00 |
Common Stock | Series B-1 Preferred Stock | Disposition | 2016-10-31 | 4,689,657 | $0.00 | 669,951 | $0.00 |
Common Stock | Series B-2 Preferred Stock | Disposition | 2016-10-31 | 4,362,472 | $0.00 | 623,210 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2022-04-01 | No | 4 | X | Direct | |
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Footnotes
- The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 435 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 80,223 shares, after deducting the aggregate exercise price.
- The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, Krishna "Kittu" Kolluri, David M. Mott, Scott D. Sandell, Ravi Viswanathan and Harry R. Weller. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 securities in which the Indirect Reporting Persons have no pecuniary interest.
- Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.